About PrIME Biologics
PrIME Biologics (PrIME) is a Singapore based company commissioning a plasma fractionation facility in Singapore to address the US$1b Asian Therapeutic Plasma products market. PrIME is using the PrIME Technology in association with GE Healthcare based Chromatography in a process called PrIME +.
Currently much of the plasma collected in Asia and other parts of the world is underutilised. If this plasma could be used to manufacture therapeutic plasma products much of the world shortage of plasma products could be addressed and many, possibly millions, of lives could be saved. At PrIME Biologics, we value the potential and ability to save lives and to provide safe and affordable plasma based therapeutics. We aim to achieve this through the use of our revolutionary PrIME Technology to process the plasma that is currently underutilised by many emerging countries.
The History of the Development of the PrIME Technology
Making Therapeutic Plasma Products for You
PrIME Biologics was established to manufacture therapeutic plasma products at the highest levels of quality and safety. This is achieve while also increasing the total amount of therapeutic products produced from each litre of plasma. PrIME Biologics goal of ‘Safer Plasma Fractionation Through Innovation’ articulates not only the characteristics of this innovative technology but the ideology of the company as well.
Today PrIME Biologics is refurbishing and recommissioning our Singapore cGMP therapeutic plasma manufacturing facility in Science Park II. We expect this to be completed by the first quarter 2015. From that time onwards we will be able to process plasma in an accredited cGMP facility. Specifically PrIME Biologics will be initially processing human plasma to produce:
The PrIME Biologics Technology
PrIME stands for Preparative Isolation by Membrane Electrophoresis technology. This is the technology used by PrIME Biologics to manufacture its therapeutic plasma products. The PrIME technology is a disposable, modular manufacturing process and is fully scalable. The system can process any volume from 20L to 1,000,000L based on a standard 50L cartridge.
The PrIME process works in an electrical environment as opposed to being ‘pressure’ driven system. Using the natural charge found on proteins, the PrIME process enables the highly selective purification of the target molecules. The fact that most cellular membranes in nature also possess a charge means that pathogens such as viruses and bacteria can also be selectively removed by this system.
The PrIME plasma process offers a number of advantages over the existing plasma fractionation processes. The existing processes are mostly built on the original Cohn fractionation process which dates back to WWII. The advent of column chromatography has enhanced the selectivity and safety of the existing process. By comparison the PrIME Biologics process provides a higher final product yield, shorter production time and great safety.
PrIME Biologics has been created by a dedicated team working for over 20 years to bring the PrIME Technology to market. We are proud of the Board and the Management Team which has evolved over this 20 year period into a tight well balanced group focused on delivering ‘Safer Plasma Fractionation Through Innovation’.
PrIME Biologics is currently capable of manufacturing therapeutic Albumin, IVIG, FVIII and FIX from human plasma. We are interested in developing other therapeutic plasma based products that are of interest to our customers. Specifically, we are interested in developing hyperimmune therapies and speciality plasma therapeutics.
We encourage you to contact us at PrIME Biologics. Please let us know how we can be of help to your business and customers.